Clinical Trials Browser

Completed × Erlotinib Hydrochloride × 30 days × Clear all

NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT01350817 2026-05-15

TARSEQ

Phase 2 Completed

156 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung